Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6904
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B ; volume:7 ; number:1 ; day:23 ; month:10 ; year:2007 ; pages:1-6 ; date:12.2007
BMC clinical pharmacology ; 7, Heft 1 (23.10.2007), 1-6, 12.2007
- Urheber
-
Reynolds, Jennifer M.
- Beteiligte Personen und Organisationen
-
El Bissati, Kamal
Brandenburg, Jens
Günzl, Arthur
Mamoun, Choukri Ben
SpringerLink (Online service)
- DOI
-
10.1186/1472-6904-7-13
- URN
-
urn:nbn:de:1111-2016072030063
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Reynolds, Jennifer M.
- El Bissati, Kamal
- Brandenburg, Jens
- Günzl, Arthur
- Mamoun, Choukri Ben
- SpringerLink (Online service)
Ähnliche Objekte (12)
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
Bortezomib
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Graphene Oxide Nanoscale Platform Enhances the Anti‐Cancer Properties of Bortezomib in Glioblastoma Models
Novel artemisinin-based antiviral, antimalarial and anticancer hybrid compounds via click chemistry
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
Bortezomib
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Graphene Oxide Nanoscale Platform Enhances the Anti‐Cancer Properties of Bortezomib in Glioblastoma Models
Novel artemisinin-based antiviral, antimalarial and anticancer hybrid compounds via click chemistry
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
Bortezomib
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Graphene Oxide Nanoscale Platform Enhances the Anti‐Cancer Properties of Bortezomib in Glioblastoma Models
Novel artemisinin-based antiviral, antimalarial and anticancer hybrid compounds via click chemistry
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma